EMA Authorised: Karvezide (irbesartan;hydrochlorothiazide) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA authorised Karvezide, a fixed-dose combination of irbesartan and hydrochlorothiazide, for the treatment of hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Karvezide (irbesartan and hydrochlorothiazide)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Sanofi Winthrop Industrie. Decision date: 18/09/2025